AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and 150mg doses. This approval allows the company to launch Lynparza in India for the maintenance treatment of advanced or recurrent endometrial cancer in adults who have not progressed following first-line treatment with Durvalumab and platinum-based chemotherapy, pending further approvals.
